This segment focuses on the research, development, and commercialization of advanced cell therapies, primarily for sports medicine and severe burn care. Key products include MACI, an autologous cellularized scaffold for cartilage repair in the knee, and Epicel, a permanent skin replacement for burn patients. Research and development activities include ongoing clinical trials and studies to expand the applications of these therapies and improve patient outcomes. Technologies employed involve cell culture, tissue engineering, and scaffold design. The segment addresses the needs of patients with cartilage defects and severe burns, offering innovative solutions to improve their quality of life. Market positioning is strong due to the unique nature of autologous cell therapies and the lack of direct competitors for some products. Future opportunities include expanding the use of MACI and Epicel, as well as developing new cell-based therapies. Regulatory and clinical aspects are critical, with a focus on obtaining and maintaining FDA approvals and adhering to stringent manufacturing standards. Partnerships and collaborations are essential for clinical trials and market access.

This segment encompasses the development and commercialization of specialty biologics, including NexoBrid, a biological orphan product for eschar removal in burn patients. Research and development activities focus on clinical trials and regulatory submissions to expand the availability of these products. Technologies and methodologies include advanced wound care and biological product manufacturing. The segment addresses the needs of patients with severe burns, providing innovative solutions for wound healing and improved patient outcomes. Market positioning is strong due to the unique nature of the products and the unmet medical needs they address. Future opportunities include expanding the use of NexoBrid and developing new biologics for burn care. Regulatory and clinical aspects are critical, with a focus on obtaining and maintaining FDA approvals and adhering to stringent manufacturing standards. Partnerships and collaborations are essential for clinical trials and market access.